Εμφάνιση απλής εγγραφής

Prevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEPO): A prospective, open label, randomized trial by the hellenic cooperative oncology group

dc.contributor.authorBamias, A. T.en
dc.contributor.authorAravantinos, Gerasimosen
dc.contributor.authorKalofonos, H. P.en
dc.contributor.authorTimotheadou, N.en
dc.contributor.authorSiafaka, V.en
dc.contributor.authorVlahou, I.en
dc.contributor.authorJaninis, D.en
dc.contributor.authorPectasides, Dimitriosen
dc.contributor.authorPavlidis, Nicholasen
dc.contributor.authorFountzilas, Georgeen
dc.creatorBamias, A. T.en
dc.creatorAravantinos, Gerasimosen
dc.creatorKalofonos, H. P.en
dc.creatorTimotheadou, N.en
dc.creatorSiafaka, V.en
dc.creatorVlahou, I.en
dc.creatorJaninis, D.en
dc.creatorPectasides, Dimitriosen
dc.creatorPavlidis, Nicholasen
dc.creatorFountzilas, Georgeen
dc.date.accessioned2018-06-22T09:52:25Z
dc.date.available2018-06-22T09:52:25Z
dc.date.issued2003
dc.identifier.urihttps://gnosis.library.ucy.ac.cy/handle/7/41346
dc.description.abstractObjectives: Platinum compounds are commonly associated with significant anemia. Erythropoietin administration has been found effective in correcting anemia in patients with solid tumors receiving chemotherapy. We conducted a randomized, open label study to assess the efficacy of erythropoietin in preventing transfusions and significant anemia (hemoglobin 0.9 or non-responders. Conclusions: rHuEPO at a dose of 10,000 U thrice weekly prevents transfusions and development of significant anemia in patients with solid tumors receiving platinum-based chemotherapy. Copyright © 2003 S. Karger AG, Basel.en
dc.language.isoengen
dc.sourceOncologyen
dc.subjectGreeceen
dc.subjectArticleen
dc.subjectCancer chemotherapyen
dc.subjectHumanen
dc.subjectNeoplasmsen
dc.subject80 and overen
dc.subjectAgeden
dc.subjectHumansen
dc.subjectAdulten
dc.subjectAgeden
dc.subjectCancer patienten
dc.subjectControlled studyen
dc.subjectFemaleen
dc.subjectMajor clinical studyen
dc.subjectMiddle ageden
dc.subjectPriority journalen
dc.subjectAntineoplastic combined chemotherapy protocolsen
dc.subjectDiarrheaen
dc.subjectDrug effecten
dc.subjectDrug efficacyen
dc.subjectFebrile neutropeniaen
dc.subjectInfectionen
dc.subjectNeutropeniaen
dc.subjectProspective studiesen
dc.subjectPlatinumen
dc.subjectPrognosisen
dc.subjectFeveren
dc.subjectTreatment outcomeen
dc.subjectSolid tumoren
dc.subjectMaleen
dc.subjectHeart infarctionen
dc.subjectRisk factorsen
dc.subjectAnemiaen
dc.subjectBleedingen
dc.subjectBlood transfusionen
dc.subjectErythropoietinen
dc.subjectHypercalcemiaen
dc.subjectHypertensionen
dc.subjectHypochromicen
dc.subjectIntestine obstructionen
dc.subjectOrganoplatinum compoundsen
dc.subjectPericarditisen
dc.subjectPlatinum chemotherapyen
dc.subjectQuality of lifeen
dc.subjectRecombinanten
dc.subjectRecombinant erythropoietinen
dc.subjectSide effecten
dc.subjectSolid tumorsen
dc.subjectVomitingen
dc.titlePrevention of anemia in patients with solid tumors receiving platinum-based chemotherapy by recombinant human erythropoietin (rHuEPO): A prospective, open label, randomized trial by the hellenic cooperative oncology groupen
dc.typeinfo:eu-repo/semantics/article
dc.identifier.doi10.1159/000067766
dc.description.volume64
dc.description.issue2
dc.description.startingpage102
dc.description.endingpage110
dc.author.facultyΙατρική Σχολή / Medical School
dc.author.departmentΙατρική Σχολή / Medical School
dc.type.uhtypeArticleen
dc.contributor.orcidPavlidis, Nicholas [0000-0002-2195-9961]
dc.contributor.orcidAravantinos, Gerasimos [0000-0002-2106-1713]
dc.contributor.orcidKalofonos, H. P. [0000-0002-3286-778X]
dc.gnosis.orcid0000-0002-2195-9961
dc.gnosis.orcid0000-0002-2106-1713
dc.gnosis.orcid0000-0002-3286-778X


Αρχεία σε αυτό το τεκμήριο

ΑρχείαΜέγεθοςΤύποςΠροβολή

Δεν υπάρχουν αρχεία που να σχετίζονται με αυτό το τεκμήριο.

Αυτό το τεκμήριο εμφανίζεται στις ακόλουθες συλλογές

Εμφάνιση απλής εγγραφής